OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

MorphoSys AG/  DE0006632003  /

Cboe Europe CXE
6/24/2024  10:51:04 AM Chg. - Volume Bid10:02:00 AM Ask9:02:04 AM Market Capitalization Dividend Y. P/E Ratio
67.63EUR - 149
Turnover: 10,076.13		 -Bid Size: - -Ask Size: - 2.55 bill.EUR - -
TeleTrader 4/11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 3/12 Germany clears Novartis' MorphoSys $2.9B deal
TeleTrader 2/5 Novartis to acquire MorphoSys for $2.9B
GlobeNewswire 6/3/2021 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire 6/2/2021 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire 4/27/2020 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire 10/28/2019 MOR106 clinical development in atopic dermatitis stopped for futility
GlobeNewswire 4/23/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 4/23/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 9/13/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 9/13/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 9/12/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 9/12/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 7/19/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 7/19/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 5/1/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 5/1/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 4/19/2018 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
GlobeNewswire 2/17/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 2/17/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 9/27/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 9/27/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 8/31/2017 Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/E...
GlobeNewswire 12/15/2016 Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MO...
GlobeNewswire 12/13/2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...